Navigation Links
AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
Date:8/14/2008

SINGAPORE, Aug. 15 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced an innovative new partnership with the National Cancer Centre Singapore (NCCS) and the National University Hospital (NUH) to develop anti-cancer compounds. The collaboration, which is spelt out in a Memorandum of Understanding (MOU) that was signed today, aims to further build AstraZeneca's drug development capabilities in Asia and ultimately speed up access to new medicines of potential benefit to patients with inoperable Hepatocellular Carcinoma (HCC). HCC is a cancer that is particularly prevalent in Asia and accounts for approximately one million deaths annually worldwide.(1) Studies have also shown that more than 90 per cent of those afflicted with the cancer die within five years due to its inoperability.(1)

Dr. Brent Vose, Vice President of AstraZeneca's Oncology Therapeutic Area said: "AstraZeneca is committed to the research and development of new, targeted anti-cancer therapies in Asia to improve the lives of cancer patients, beginning with those affected by HCC. There is a huge unmet need for treatment of liver cancer in Asia, and particularly East Asia, where there are three-quarters of the world's HCC patients.(2) We have a number of promising candidates in development and look forward to seeing the results of some key studies throughout the next year."

Under the MOU, AstraZeneca and the Singapore institutions will be entering into a collaborative agreement that spans both clinical and pre-clinical development activities. The partnership also includes a Training Programme placement with the Manchester Cancer Research Centre, with whom AstraZeneca has a formal research alliance. Supported in part by the Singapore Economic Developm
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
2. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
3. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
4. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
5. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
8. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
9. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
10. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Congressional Leaders to Introduce Legislation , WASHINGTON , ... Congressional Network (ACPCN) will join congressional leaders tomorrow to ... Savings Act." The bill by U.S. Rep. G.K. ... management (PBM) companies for medications. , "Congress is prepared ...
... AMD LASERS, the world leader in comprehensive and affordable ... Waclawik as Chief Operating Officer. In this newly created ... operations, procurement, production, quality assurance, and general financial oversight ... effort on the next-generation of product development in order ...
Cached Medicine Technology:Pharmacists Work with Congress to Address PBM Abuses 2AMD LASERS Announces the Addition of Bart Waclawik, New Chief Operating Officer 2
(Date:4/23/2014)... by a researcher from the Cancer Science Institute of ... has identified the cancer specific stem cell which causes ... developing new drugs for the treatment of this disease ... led by Dr Chan Shing Leng, Research Assistant Professor ... a cancer-specific variant of a cell surface protein, CD44v8-10, ...
(Date:4/23/2014)... may prevent the depletion of self-control, according to research ... the Association for Psychological Science. , Self-control can be ... focus attention on a boring textbook are hard things ... this difficulty: Exerting self-control for a long period seems ... subsequent tasks. , "It is as if self-control is ...
(Date:4/22/2014)... the New Jersey Institute of Technology (NJIT) today ... the launch of the New Jersey Innovation Institute ... model for business innovation through the leveraging of ... U.S. Senator Cory Booker, Panasonic Corp. of North ... Lieutenant Governor Kim Guadagno, New Jersey Secretary of ...
(Date:4/22/2014)... 2014 Researchers at UT Southwestern Medical Center are ... depression . , A team of physician-scientists at ... ghrelin (a hormone with natural anti-depressant properties) works inside ... new treatment for depression in the form of a ... study, published online in April,s issue of Molecular ...
(Date:4/22/2014)... 22, 2014) The International Communication Association will ... Seattle, Washington. The theme of the 2014 conference ... a networked and digital society. , Featuring over ... over 2,200 Communication scholars representing over 40 countries, ... communication conference in the world. This year,s conference ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... 4 (HealthDay News) -- The quality of family mealtimes ... research suggests. In the study, U.S. researchers observed ... children aged 5 to 12 with persistent asthma. ... or in a particular season, children with persistent asthma ...
... , FRIDAY, Feb. 4 (HealthDay News) -- The death of ... typically seen directed toward live infants, but it,s unclear whether ... may help improve understanding of how chimpanzees, one of humans, ... study authors noted. In the study, the researchers ...
... News) -- Safety labels that outline concerns about medications, ... within drug categories, a new study suggests. These ... a single class of drugs, according to a team ... team also advised that supplemental warnings (for example, following ...
... is blamed on a failure of innovative drive in the ... of venture capital to invest in early stage research, or ... , A research centre funded by the Economic and Social ... industry regulatory system must be an important part of the ...
... Gordon HealthDay Reporter , THURSDAY, Feb. 3 ... reduce symptoms of attention-deficit hyperactivity disorder (ADHD) in young ... the ages of 4 and 8 were placed on ... ADHD symptoms diminished in 78 percent of them. And, ...
... THURSDAY, Feb. 3 (HealthDay News) -- Although blacks make up only ... of all diagnosed cases of HIV, federal health officials reported Thursday. ... times that of whites, and the rate for black women is ... data from 37 states by the U.S. Centers for Disease Control ...
Cached Medicine News:Health News:Quality of Family Mealtimes May Affect Kids' Asthma 2Health News:'Black Box' Drug Warning Labels Applied Inconsistently: Study 2Health News:Tipping points -- the future of the pharmaceutical industry 2Health News:Restrictive Diet May Reduce ADHD Symptoms 2Health News:Restrictive Diet May Reduce ADHD Symptoms 3Health News:Restrictive Diet May Reduce ADHD Symptoms 4Health News: Burden of HIV Highest for Blacks, CDC Reports 2Health News: Burden of HIV Highest for Blacks, CDC Reports 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: